Emergent Z Score
EBS  Stock  USD 28.94 0.45 1.53% 
Emergent  Z Score 
Emergent Z Score Analysis
Emergent Biosolutions' ZScore is a simple linear, multifactor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..2019  2020  2021 (projected)  
Long Term Debt to Equity  0.73  0.58  0.5 
Interest Coverage  2.97  13.86  10.22 
Z Score  =  Sum Of   5 Factors 
Current Emergent Biosolutions Z Score  1.6 
Most of Emergent Biosolutions' fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Emergent Biosolutions is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
 
 
 
 

Emergent Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Emergent Biosolutions is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Z Score. Since Emergent Biosolutions' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Emergent Biosolutions' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Emergent Biosolutions' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate ZScore one would need to know current working capital of the company, its total assets, and liabilities, amount of latest retained earnings as well as earnings before interest and tax. ZScore can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with ZScores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a socalled 'grey area' with scores of less than 1, indicating the high probability of distress. Z Score is used widely by financial auditors, accountants, money managers, loan processers, wealth advisers, as well as day traders. In the last 25 years, many financial models that utilize z score has been proved to be successful as a predictor of corporate bankruptcy.
Compare to competition 
According to the company's disclosures, Emergent Biosolutions has a Z Score of 1.6. This is 76.3% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturersâ€”Specialty & Generic industry. The z score for all United States stocks is 81.65% higher than that of the company.
Emergent Biosolutions Current Valuation Drivers
We derive many important indicators used in calculating different scores of Emergent Biosolutions from analyzing Emergent Biosolutions' financial statements. These drivers represent accounts that assess Emergent Biosolutions' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Emergent Biosolutions' important valuation drivers and their relationship over time.
2017  2018  2019  2020  2021  2022 (projected)  
Net Income Per Employee  65.76 K  36.77 K  29.72 K  434.67 K  95.57 K  83.02 K  
Revenue Per Employee  446.56 K  458.89 K  603.05 K  2.22 M  742.01 K  633.64 K  
Average Assets  1 B  1.4 B  2.28 B  2.56 B  2.91 B  2.3 B  
Earnings Before Interest Taxes and Depreciation Amortization EBITDA  167.8 M  153.6 M  226.5 M  553 M  472.7 M  510.02 M  
Earnings Before Interest Taxes and Depreciation Amortization USD  167.8 M  153.6 M  226.5 M  553 M  472.7 M  510.02 M  
Earnings before Tax  118.6 M  81.5 M  77.4 M  407.2 M  314.4 M  339.22 M  
Average Equity  701.76 M  949.29 M  1.02 B  1.24 B  1.55 B  1.26 B  
Enterprise Value  1.83 B  2.69 B  3.47 B  5.21 B  2.78 B  2.6 B  
Free Cash Flow  153.3 M  (30.3 M)  101.1 M  395 M  96.1 M  91.2 M  
Invested Capital  635.6 M  1.69 B  1.77 B  1.82 B  2.02 B  1.67 B  
Invested Capital Average  742.21 M  911.65 M  1.67 B  1.77 B  2.01 B  1.61 B  
Market Capitalization  1.92 B  3.02 B  2.79 B  4.75 B  2.34 B  2.32 B  
Tangible Asset Value  901.5 M  1.21 B  1.35 B  1.95 B  2.13 B  1.75 B  
Working Capital  385.3 M  420.4 M  469.9 M  811.4 M  898.3 M  723.74 M 
Emergent Fundamentals
Return On Equity  10.17 %  
Return On Asset  6.77 %  
Profit Margin  8.96 %  
Operating Margin  17.50 %  
Current Valuation  2.17 B  
Shares Outstanding  53.8 M  
Shares Owned by Insiders  10.10 %  
Shares Owned by Institutions  87.93 %  
Number of Shares Shorted  3.44 M  
Price to Earning  7.29 X  
Price to Book  1.08 X  
Price to Sales  0.93 X  
Revenue  1.76 B  
Gross Profit  804.1 M  
EBITDA  427.9 M  
Net Income  157.5 M  
Cash and Equivalents  436 M  
Cash per Share  8.68 X  
Total Debt  861.5 M  
Debt to Equity  0.55 %  
Current Ratio  4.41 X  
Book Value Per Share  28.36 X  
Cash Flow from Operations  278.7 M  
Short Ratio  6.16 X  
Earnings Per Share  4.18 X  
Price to Earnings To Growth  (1.45) X  
Number of Employees  2.42 K  
Beta  0.96  
Market Capitalization  1.64 B  
Total Asset  1.04 B  
Retained Earnings  379.1 M  
Working Capital  437.8 M  
Current Asset  537.41 M  
Current Liabilities  99.61 M  
Z Score  1.6 
About Emergent Biosolutions Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Emergent Biosolutions's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Emergent Biosolutions using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Emergent Biosolutions based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats in the United States. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland. Emergent Biosolutions operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 2416 people.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Emergent Biosolutions without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.riskadjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Center Now
Portfolio CenterAll portfolio management and optimization tools to improve performance of your portfolios 
All Next  Launch Module 
Pair Trading with Emergent Biosolutions
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Emergent Biosolutions position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Emergent Biosolutions will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Emergent Biosolutions could be a great tool in your taxloss harvesting strategies, allowing investors a quick way to find a similarenough asset to replace Emergent Biosolutions when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Emergent Biosolutions  that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Emergent Biosolutions to buy it.
The correlation of Emergent Biosolutions is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between 1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Emergent Biosolutions moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Emergent Biosolutions moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Emergent Biosolutions can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better riskadjusted return on your portfolios.Continue to Emergent Biosolutions Piotroski F Score and Emergent Biosolutions Valuation analysis. Note that the Emergent Biosolutions information on this page should be used as a complementary analysis to other Emergent Biosolutions' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Complementary Tools for Emergent Stock analysis
When running Emergent Biosolutions price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.
Commodity Channel IndexUse Commodity Channel Index to analyze current equity momentum  Go  
Stock ScreenerFind equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.  Go  
Probability Of BankruptcyGet analysis of equity chance of financial distress in the next 2 years  Go  
Technical AnalysisCheck basic technical indicators and analysis based on most latest market data  Go  
Technical AnalysisCheck basic technical indicators and analysis based on most latest market data  Go  
Portfolio VolatilityCheck portfolio volatility and analyze historical return density to properly model market risk  Go  
Equity ForecastingUse basic forecasting models to generate price predictions and determine price momentum  Go  
Insider ScreenerFind insiders across different sectors to evaluate their impact on performance  Go  
Fundamentals ComparisonCompare fundamentals across multiple equities to find investing opportunities  Go  
Earnings CallsCheck upcoming earnings announcements updated hourly across public exchanges  Go 
Is Emergent Biosolutions' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Emergent Biosolutions. If investors know Emergent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Emergent Biosolutions listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY 0.022  Market Capitalization 1.5 B  Quarterly Revenue Growth YOY 0.39  Return On Assets 0.049  Return On Equity 0.0631 
The market value of Emergent Biosolutions is measured differently than its book value, which is the value of Emergent that is recorded on the company's balance sheet. Investors also form their own opinion of Emergent Biosolutions' value that differs from its market value or its book value, called intrinsic value, which is Emergent Biosolutions' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Emergent Biosolutions' market value can be influenced by many factors that don't directly affect Emergent Biosolutions' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Emergent Biosolutions' value and its price as these two are different measures arrived at by different means. Investors typically determine Emergent Biosolutions value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Emergent Biosolutions' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.